Abstract
Iron deficiency anemia is common in people with chronic kidney disease (CKD) and its importance in supporting erythropoiesis is unquestioned especially in those patients treated with erythropoietin. Clinical symptomatology such as fatigability, cold intolerance, failure to concentrate and poor effort intolerance is often attributed to anemia or uremia. That iron deficiency, per se, can cause these symptoms is poorly recognized. Clinical and animal studies that support the benefits of iron supplementation, independent of increasing hemoglobin, such as those on immune function, physical performance, thermoregulation, cognition, and restless leg syndrome and aluminum absorption is the subject of this narrative review.
References
1.
Finch CA, Miller LR, Inamdar AR, Person R, Seiler K, Mackler B: Iron deficiency in the rat: physiological and biochemical studies of muscle dysfunction. J Clin Invest 1976;58:447–453.
2.
Hinton PS, Giordano C, Brownlie T, Haas JD: Iron supplementation improves endurance after training in iron-depleted, nonanemic women. J Appl Physiol 2000;88:1103–1111.
3.
Brownlie T, Utermohlen V, Hinton PS, Haas JD: Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 2004;79:437–443.
4.
Hinton PS, Sinclair LM: Iron supplementation maintains ventilatory threshold and improves energetic efficiency in iron-deficient nonanemic athletes. Eur J Clin Nutr 2007;61:30–39.
5.
Friedmann B, Weller E, Mairbaurl H, Bartsch P: Effects of iron repletion on blood volume and performance capacity in young athletes. Med Sci Sports Exerc 2001;33:741–746.
6.
LaManca JJ, Haymes EM: Effects of iron repletion on VO2max, endurance, and blood lactate in women. Med Sci Sports Exerc 1993;25:1386–1392.
7.
Klingshirn LA, Pate RR, Bourque SP, Davis JM, Sargent RG: Effect of iron supplementation on endurance capacity in iron-depleted female runners. Med Sci Sports Exerc 1992;24:819–824.
8.
Beard JL: Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 2001;131:568S–579S.
9.
Verdon F, Burnand B, Stubi CL, Bonard C, Graff M, Michaud A, Bischoff T, de Vevey M, Studer JP, Herzig L, Chapuis C, Tissot J, Pecoud A, Favrat B: Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ 2003;326:1124.
10.
Haas JD, Brownlie T: Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr 2001;131:676S–688S.
11.
Patterson AJ, Brown WJ, Powers JR, Roberts DC: Iron deficiency, general health and fatigue: results from the Australian Longitudinal Study on Women’s Health. Qual Life Res 2000;9:491–497.
12.
Martinez-Torres C, Cubeddu L, Dillmann E, Brengelmann GL, Leets I, Layrisse M, Johnson DG, Finch C: Effect of exposure to low temperature on normal and iron-deficient subjects. Am J Physiol 1984;246:R380–R383.
13.
Youdim MB, Yehuda S: The neurochemical basis of cognitive deficits induced by brain iron deficiency: involvement of dopamine-opiate system. Cell Mol Biol (Noisy-le-grand) 2000;46:491–500.
14.
Connor JR, Menzies SL, Burdo JR, Boyer PJ: Iron and iron management proteins in neurobiology. Pediatr Neurol 2001;25:118–129.
15.
Bruner AB, Joffe A, Duggan AK, Casella JF, Brandt J: Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet 1996;348:992–996.
16.
Murray-Kolb LE, Beard JL: Iron treatment normalizes cognitive functioning in young women. Am J Clin Nutr 2007;85:778–787.
17.
McCann JC, Ames BN: An overview of evidence for a causal relation between iron deficiency during development and deficits in cognitive or behavioral function. Am J Clin Nutr 2007;85:931–945.
18.
Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP: Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 2000;54:1698–1700.
19.
Allen RP, Barker PB, Wehrl F, Song HK, Earley CJ: MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001;56:263–265.
20.
Berger K, von Eckardstein A, Trenkwalder C, Rothdach A, Junker R, Weiland SK: Iron metabolism and the risk of restless legs syndrome in an elderly general population: the MEMO-Study. J Neurol 2002;249:1195–1199.
21.
Sloand JA, Shelly MA, Feigin A, Bernstein P, Monk RD: A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004;43:663–670.
22.
Mackler B, Person R, Ochs H, Finch CA: Iron deficiency in the rat: effects on neutrophil activation and metabolism. Pediatr Res 1984;18:549–551.
23.
Chandra RK: Reduced bactericidal capacity of polymorphs in iron deficiency. Arch Dis Child 1973;48:864–866.
24.
Sazawal S, Black RE, Ramsan M, Chwaya HM, Stoltzfus RJ, Dutta A, Dhingra U, Kabole I, Deb S, Othman MK, Kabole FM: Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. Lancet 2006;367:133–143.
25.
Cannata JB, Fernandez-Soto I, Fernandez-Menendez MJ, Fernandez-Martin JL, McGregor SJ, Brock JH, Halls D: Role of iron metabolism in absorption and cellular uptake of aluminum. Kidney Int 1991;39:799–803.
26.
Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A: A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006;26:445–454.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.